Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Lupin posts Rs 123...

    Lupin posts Rs 123 crore net loss in Q2

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-11-07T09:15:12+05:30  |  Updated On 7 Nov 2019 9:15 AM IST
    Lupin posts Rs 123 crore net loss in Q2

    Lupin said it has agreed to pay Rs 450.06 crore as settlement in connection with the lawsuit in the US and, accordingly, a provision of Rs 379.18 crore has been made during the quarter.


    Mumbai: Drug maker Lupin on Wednesday reported a consolidated net loss of Rs 123.44 crore for the second quarter ended September 30, impacted by provisioning for one-time payment to settle a lawsuit in the US and loss in divestment of injectables business in Japan. The Mumbai-based company had posted a net profit of Rs 288.45 crore in the July-September period of 2018-19.


    Total revenue from operations stood at Rs 4,359.65 crore for the second quarter as against Rs 3,951.06 crore in the year-ago period, Lupin Ltd said in a regulatory filing.


    The firm said it has agreed to pay Rs 450.06 crore as settlement in connection with the lawsuit in the US and, accordingly, a provision of Rs 379.18 crore has been made during the quarter.


    Besides, the divestment of Kyowa CritiCare Co (KCC) was completed during the period with the resultant loss on divestment pegged at Rs 167.3 crore, it added.


    Read Also: Lupin gets USFDA nod for generic version of Levoxyl tablets to treat hypothyroidism


    "The reported performance for the quarter was bolstered by the NCE licensing income but impacted by one-off items, adjusted for which, the operational performance was as expected," Lupin Ltd Managing Director Nilesh Gupta said.


    The US business has now stabilised and will grow based on ramp up of our in-line products and levothyroxine and the launch of injectables portfolio, he added.


    "Markets like India continue to deliver solid growth. The next financial year is now looking very strong with important growth drivers like India, the in-line generic business in the US coupled with important launches like generic Albuterol in US and Fostair and Etanercept in Europe," Gupta said.


    Read Also: Lupin gets USFDA nod for generic equivalent of Depakote ER Tablets to treat epilepsy in US

    generic Albuterolinjectables businessKCCKyowa CritiCare ColawsuitLevothyroxineLupinlupin injectablelupin japanNilesh Guptapharmapharma companypharma news
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok